Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

This is a Phase I/Ib study whose purpose is to find out if combining an experimental drug called binimetinib with pembrolizumab is beneficial in people who have advanced non-small cell lung cancer. This study may also see if the combination is safe and may also find the best dose of binimetinib that should be added to pembrolizumab.

Trial Details

NCT ID
NCT03991819
Phase
PHASE1
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Binimetinib
  • Pembrolizumab
Locations (sample)
  • Calgary, Alberta, Canada|51.05011,-114.08529
  • Toronto, Ontario, Canada|43.70643,-79.39864
  • Regina, Saskatchewan, Canada|50.45008,-104.6178
  • Saskatoon, Saskatchewan, Canada|52.13238,-106.66892

Key Eligibility Criteria

  • Histologically confirmed diagnosis of non-small cell lung carcinoma with tumour PDL-1 TPS≥50% by 22C3 pharmDx immunohistochemistry. Patients must h…
  • Must agree to use methods to prevent pregnancy as agreed upon between the investigator and the participant for at least 120 days after the last dos…
  • The participant provides written informed consent for the trial.
  • Have measurable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →